Detalhe da pesquisa
1.
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.
Lancet Infect Dis
; 22(11): 1596-1605, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35963275